OsmanKostekMD· @OncologyMarwarD · X·· 2 天前评分70
正文 · 原文
🚨 ESMO26 | G-HOPE-001
Arcotatug tavatecan vs chemotherapy in CLDN18.2-high advanced gastric/GEJ cancer (3L+):
✅ PFS: HR 0.47
✅ OS: 10.2 vs 6.9 months (HR 0.57)
🎯 Promising new option for heavily pretreated patients!
#ESMO26 #GastricCancer #ADC
215 浏览 · 4 赞 · 1 转发 · 0 回复
会议摘要
LBA77按 Proffered paper 1: Gastrointestinal tumour, upper digestive 对上
Arcotatug tavatecan (IBI343/TAK-921) versus treatment of physician’s choice (TPC) in previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA): First interim analysis of the randomized, open-label, phase 3, G
https://esmocongress.esmo.org来源：OsmanKostekMD · x.com